Robert J. Alpern - Dec 31, 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Director
Signature
Steven L. Scrogham, attorney-in-fact for Robert J. Alpern
Stock symbol
ABBV
Transactions as of
Dec 31, 2022
Transactions value $
$7,434
Form type
4
Date filed
1/3/2023, 04:06 PM
Previous filing
Nov 25, 2022
Next filing
Apr 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Stock Equivalent Units Award $7.43K +46 +0.53% $161.61 8.72K Dec 31, 2022 Common Stock 46 $161.61 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2 Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F3 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.